Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Oct;198(10):962-965.
doi: 10.1007/s00066-022-01968-5. Epub 2022 Jun 22.

[Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials]

[Article in German]
Etienne Mathier  1 , Astrid Heusel  1 , Mohamed Shelan  2
Affiliations
Clinical Trial

[Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials]

[Article in German]
Etienne Mathier et al. Strahlenther Onkol. 2022 Oct.
No abstract available

PubMed Disclaimer

References

Literatur

    1. Murthy V, Maitre P, Kannan S et al (2021) Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol 39(11):1234–1242. https://doi.org/10.1200/JCO.20.03282 - DOI - PubMed
    1. Kerkmeijer LGW, Groen VH, Pos FJ et al (2021) Focal boost to the Intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39(7):787–796. https://doi.org/10.1200/JCO.20.02873 - DOI - PubMed
    1. Attard G, Murphy L, Clarke NW et al (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 399(10323):447–460. https://doi.org/10.1016/S0140-6736(21)02437-5 - DOI - PubMed - PMC
    1. Xie W, Regan M, Buyse M, Halabi S, Kantoff P, Sartor O, Soule H, Berry D, Clarke N, Collette L, D’Amico A, Lourenco R, Dignam J, Eisenberger M, James N, Fizazi K, Gillessen S, Loriot Y, Mottet N, Parulekar W, Sandler H, Spratt D, Sydes M, Tombal B, Williams S, Sweeney C (2020) Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation. J Clin Oncol 38(26):3032–3041 - DOI
    1. Xie W, Regan M, Buyse M, Halabi S, Kantoff P, Sartor O, Soule H, Clarke N, Collette L, Dignam J, Fizazi K, Paruleker W, Sandler H, Sydes M, Tombal B, Williams S, Sweeney C (2017) Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol 35(27):3097–3104 - DOI

Publication types

LinkOut - more resources